Brind.

Sustained enforcement against misleading GLP-1 marketing claims by the FDA against regulated companies.

1 report, 1 independent Updated Jun 30
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

Sustained enforcement against misleading GLP-1 marketing claims by the FDA against regulated companies.

How it developed

Newest first. Tap a step to see who reported it.
  1. Eli Lilly warns the FDA about black market drug sales, while U.S. Customs and Border Protection intercepts shipments of illicit GLP-1 drugs.Sub-event
  2. Sustained enforcement against misleading GLP-1 marketing claims by the FDA against regulated companies.1 source

Coverage

Newest first; wire copies grouped